Switching from injectable to oral GLP-1 maintains significant weight loss

An average reduction of 4kg (8.8lbs) was recorded among participants who transitioned from injectable GLP-1 medications to the oral version of Wegovy, according to findings presented at the annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. This represents a 4% decrease in body weight over a three-month period.

OCTANE trial results explained

The OCTANE study tracked 200 individuals using the pill outside of a controlled clinical trial environment. It is the first investigation to monitor real-world usage of this specific tablet formulation. The data suggests that those who moved away from needles continued to shed pounds, challenging previous assumptions about the efficacy of oral alternatives compared to injections.

George Godfrey, UK director at drugmaker Novo Nordisk, stated that some patients find oral therapy more convenient when combined with dietary and exercise adjustments. He noted that the results are encouraging because most participants adhered to their medication schedule consistently. This adherence allowed them to align their weight loss journey with their lifestyle preferences while still achieving therapeutic outcomes.

Mechanism of oral semaglutide

Unlike traditional peptide-based injections, which are larger molecules typically broken down by stomach acid and thus require needle administration, the new pills utilize a "non-peptide small molecule." This structural difference allows the drug to survive gastric conditions and be absorbed directly by the gut.

Professor Louis Aronne, co-lead of the study from Weill Cornell Medicine in New York, emphasized that the oral form does not need refrigeration. Furthermore, it eliminates the strict protocols associated with injectables, such as fasting, limited water intake, or waiting 30 minutes before eating. Aronne previously told the Mirror that these logistical barriers often contribute to treatment discontinuation.

Long-term weight management potential

Injectable GLP-1 drugs have demonstrated significant weight loss capabilities, reducing up to a quarter of a user’s body weight. However, many patients stop using them due to high costs or aversion to needles, leading to rapid weight regain. The oral alternative is being promoted as a method to maintain long-term weight control for those unwilling to continue self-injecting.

Aronne, who has researched human appetite since the 1980s, suggested that weight loss pills could eventually serve a preventative role. He proposed that healthy-weight young adults might take these medications to avoid becoming overweight, similar to how hypertension drugs are prescribed prophylactically. Currently, GLP-1 treatments slow digestion and reduce appetite by mimicking glucagon-like peptide 1, a hormone regulating hunger and fullness.

Access and cost implications

In the UK, the NHS prescribes Mounjaro and Wegovy injections for weight loss, while Ozempic is reserved exclusively for diabetes. Access remains rationed for the most severely obese and unwell patients, with most users relying on private prescriptions costing between £100 and £350 monthly. Proponents argue that mass production of pills could eventually lower these expenses and broaden availability.

Aronne highlighted that while the drug interacts with other medications, requiring time for adjustment, its manufacturing simplicity offers distinct advantages. He described the shift to oral semaglutide as a viable path for suitable patients, noting improvements in BMI levels below the clinical obesity threshold within the first three months. These early insights indicate a potential for individualizing obesity care through flexible treatment options.